

HPTN 046

A Phase III trial to determine the efficacy and safety of an extended regimen of nevirapine in infants born to HIV-infected women to prevent vertical HIV transmission during breastfeeding

TABLE OF CONTENTS

SECTION 1. INTRODUCTION	1-1
1.1 Sources of Procedural Information.....	1
1.2 Investigator Responsibilities	2
1.3 Study Activation Process.....	3
1.3.1 Protocol Distribution	3
1.3.2 Development & CORE Review of Site-Specific Informed Consent Forms: English Version	3
1.3.3 Development & CORE Review of Site-Specific Informed Consent Forms: Local Language Version ...	4
1.3.4 IRB/EC Review.....	4
1.3.5 Protocol Registration.....	4
1.3.6 Site-Specific Study Activation	5
Table 1-1 IRB/EC Submissions Required Prior to Study Initiation for HPTN 046	8
Table 1-2 IRB/EC Submissions Required During Study Conduct for HPTN 046	9
SECTION 2. PROTOCOL	2-1
SECTION 3. DOCUMENTATION REQUIREMENTS.....	3-1
3.1 Essential Documents	1
3.2 Participant Research Records.....	2
3.2.1 Participant Research Record Content.....	2
3.2.2 Concept of Source Documentation.....	3
3.2.3 Document Organization	4
3.2.4 Chart Notes	5
3.2.5 DataFax and Non-DataFax Forms Provided by the SDMC	5
3.3 Record Retention Requirements.....	6
3.4 Product Dispensing and Accountability Records	6
3.5 Protocol Event Reporting	6
3.6 Ancillary Studies.....	7
3.7 Study Publications.....	7
Table 3-1 Suggested Filing Structure for HPTN 046 Essential Documents	8
Table 3-2 Sample HPTN 046 Required Case History Elements and Source Document Guide	11
SECTION 4. PARTICIPANT ACCRUAL.....	4-1
4.1 Recruitment and Target Enrollment	1
4.2 Screening and Enrollment	1
4.2.1 Assignment of Participant ID Numbers	2
4.2.2 Definition of Enrollment	2
4.2.3 Screening and Enrollment Timeframe	2
4.2.4 Screening and Enrollment Log.....	2
4.2.5 Screening and Enrollment Tracking.....	2
4.3 Informed Consent for Initial Screening and Enrollment under Version 3.0.....	3
4.3.1 Deliver Required Information in an Understandable Manner	4
4.3.2 Obtain Consent in a Setting Free of Coercion.....	4
4.3.3 Confirm Participant Comprehension.....	4
4.3.4 Document the Process	5
4.4 Consent for Infant’s Continuation in the Study after Maternal Death.....	7
4.5 Informed Consent for Specimen Storage.....	7
4.6 Storage of Consent Forms	8
4.7 Eligibility Determination.....	8

4.7.1	Maternal Eligibility Criteria	8
4.7.2	Infant Enrollment Criteria	9
Table 4-1	Sample Informed Consent Assessment Tool for Enrollment in HPTN 046.....	10
Table 4-2	Sample Informed Consent Coversheet for HPTN 046.....	11

SECTION 5. PARTICIPANT FOLLOW-UP..... 5-1

5.1	Follow-up Period.....	1
5.2	Randomization	1
5.3	Follow-up Visits	2
5.3.1	Follow-up Visit Locations/Off-Site Visits	3
5.4	Scheduled Follow-up Procedures	3
5.4.1	Mothers	3
5.4.2	Infants	4
5.5	Special Circumstances Affecting Follow-up Assessments.....	4
5.5.1	Infant HIV Infection Prior to Randomization	4
5.5.2	Infant HIV Infection After Randomization	5
5.5.3	Open-Label Nevirapine Permanently Discontinued.....	5
5.5.4	Open-Label Nevirapine Never Started	5
5.5.5	Open-Label Nevirapine a Gap in Dosing	6
5.5.6	Study Drug (NVP Placebo or NVP) Discontinued or Never Started	6
5.5.7	Study Drug (NVP Placebo or NVP) a Gap in Dosing	6
5.5.8	Infant Death.....	7
5.5.9	Maternal Death.....	7
5.5.10	Early Termination of Mother and/or Infant for Reason Other than Death	7
5.5.10.1	Enrolled (Not Randomized) Mother/Infant Pair Terminated for Reason other than Death.....	8
5.5.10.2	Randomized Mother/Infant Pair Terminated for Reason other than Death	8
5.6	Follow-up Visit Scheduling.....	9
5.6.1	Target Visit Dates	9
5.6.2	Allowable Visit Windows	9
5.6.3	Missed Visits.....	9
5.6.4	Visits Conducted Over Multiple Days (“Split Visits”)	10
5.7	HIV Testing: Infants.....	10
5.7.1	Infants 15 Months of Age or Younger	10
5.7.2	Infants Older Than 15 Months of Age	11
5.8	Participant Transfers	11

SECTION 6. VISIT CHECKLISTS..... 6-1

6.1	Use of Checklists.....	1
6.2	Sequence of Procedures.....	1

Checklists:

- Maternal Screening Evaluations
- Labor and Delivery Evaluations
- Infant Birth Visit – Day 0
- Enrollment Procedures
- Infant’s Follow-up Visit – 2 and 5 weeks
- Infant’s Follow-up Visit – 6 weeks
- Randomization Procedures – 6 weeks
- Infant’s Follow-up Visit – 8 weeks
- Infant’s Follow-up Visit – 3 months
- Infant’s Follow-up Visit – 4 and 5 months
- Infant’s Follow-up Visit – 6 months
- Infant’s Follow-up Visit – 9 months
- Infant’s Follow-up Visit – 12 months
- Infant’s Follow-up Visit – 18 months
- Mother’s Follow-up Visit – 2 and 6 weeks, 3, 6, and 12 months
- Mother’s Follow-up Visit – 18 months

SECTION 7. PARTICIPANT RETENTION.....	7-1
7.1 Retention Definitions	1
7.2 Retention Requirements	1
7.3 Rationale for Retention Goals	1
7.4 Retention Plan	2
7.5 Obtaining and Updating Locator Information	2
7.6 Participant Tracking Database.....	3
7.7 Retention Tips	3
SECTION 8. STUDY DRUG RESPONSIBILITIES FOR NON-PHARMACY STAFF	8-1
8.1 Open Label NVP/Study Drug.....	1
8.1.1 HPTN 046 Open-Label NVP, Study Drug and Ancillary Supplies.....	1
8.2 Requirements Prior to Shipment to Sites.....	1
8.3 Accountability (Chain of Custody)	2
8.4 Storage of Pharmacist-Prepared Open-Label NVP/Study Drug.....	2
8.5 Dispensing of Initial “Enrollment” Supply of Open-Label Nevirapine.....	3
8.5.1 Dispensing of Enrollment Packets to Clinic Staff Prior to Enrollment	3
Figure 8-1 HPTN 046 Open-Label Nevirapine Prescription	4
Figure 8-2 HPTN 046 Enrollment/Randomization Packet Request Form	5
Figure 8-3 Enrollment Packet Label	6
Figure 8-4 HPTN 046 Record of Receipt of Infant-Specific Packets	6
Figure 8-5 HPTN 046 Record of Return of Infant-Specific Packets	7
Figure 8-6 Open-Label NVP Bottle Label.....	7
Figure 8-7 HPTN 046 Dispensing Slip – Enrollment	8
8.5.2 Dispensing Open-Label NVP by Pharmacists to Clinic Staff after Enrollment	8
8.5.3 Dispensing Open-Label NVP by Pharmacist Directly to Mothers	10
8.5.4 Dispensing Open-Label NVP for Multiple Births after Enrollment.....	10
8.6 Dispensing of Initial “Randomized” Supply of Study Drug.....	11
Figure 8-8 HPTN 046 Stud Drug Prescription.....	12
Figure 8-9 Sample HPTN 046 Protocol Randomization Record	13
8.6.1 Dispensing of Randomization Packets to Clinic Staff Prior to Randomization	14
Figure 8-10 Randomization Packet Label.....	15
Figure 8-11 Study Drug Bottle Label	15
Figure 8-12 HPTN 046 Dispensing Slip – Randomization.....	16
8.6.2 Dispensing of Study Drug by Pharmacists to Clinic Staff after Randomization.....	16
8.6.3 Dispensing of Study Drug by Pharmacist Directly to Mothers	17
8.6.4 Dispensing Study Drug for Multiple Births after Randomization.....	18
8.7 Follow-up Dispensing Procedures for Open-Label NVP and Study Drug	19
8.7.1 Open-Label NVP/Study Drug Request Slips	19
Figure 8-13 HPTN 046 Open-Label NVP/Study Drug Request Form	21
8.7.2 Dispensing of Pharmacist Prepared Infant Packets at Follow-up by Clinic Staff to Mothers	22
Figure 8-14 Infant Packet Label	23
Figure 8-15 HPTN 046 Dispensing Slip – Week 2 Visit	24
8.7.3 Dispensing Open-Label NVP/Study Drug at Follow-up by Pharmacist Directly to Mothers	24
8.8 Administration Instructions (Open-Label NVP and Study Drug) for Mothers	24
SECTION 9. CLINICAL AND COUNSELING PROCEDURES.....	9-1
9.1 Infant Feeding Options Counseling.....	1
9.2 Initial Maternal Screening Visit	1
9.2.1 Pre- and Post-test HIV Counseling	2
9.2.2 Screening Medical History and Review of Systems (ROS).....	3
9.2.3 Screening Maternal Physical Exam.....	3
9.3 Maternal Labor/Delivery (Postpartum) Screening Evaluations.....	4

9.3.1	Postpartum Infant Feeding Counseling	4
9.3.2	Postpartum Maternal Medical History and Review of Systems	4
9.3.3	Postpartum Maternal Physical Exam	5
9.4	Infant Birth Visit/Evaluations for Enrollment	5
9.4.1	Infant Birth History	6
9.4.2	Infant Birth Physical Exam	6
9.5	Maternal Follow-up Visits.....	7
9.5.1	Follow-up Infant Feeding Counseling.....	7
9.5.2	Maternal Interim Medical History and ROS	7
9.5.3	Maternal Interim Physical Exam.....	8
9.5.4	WHO Clinical Staging	8
9.6	Infant Follow-up Visits	8
9.6.1	Evaluations for Randomization.....	8
9.6.2	Infant Follow-up Medical History.....	9
9.6.3	Infant Follow-up Physical Exam.....	10
9.7	Definitions of Exam Findings/Diagnoses Identified on DataFax Forms.....	11
9.7.1	Infant Conditions.....	11
9.7.2	Maternal Conditions.....	13
9.8	Open-Label NVP and Study Drug Adherence Counseling	14
9.9	Toxicity Grading and Management.....	15
9.10	Access to HIV-Related Care	15
Table 9-1	WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents	16
SECTION 10. LABORATORY PROCEDURES		10-1
10.1	Overview and General Guidance.....	1
10.2	Overview of Laboratory Testing Locations, Specimens and Methods.....	1
10.3	Labeling Specimens and Recording Laboratory Results.....	2
10.4	SCHARP Pre-printed Labels and LDMS Specimen Tracking Sheets.....	2
Figure 10-1	Sample Specimen Tracking Sheet.....	3
10.5	The Laboratory Data Management System (LDMS)	4
10.6	Required Laboratory Assays	5
10.6.1	Local Specimen Testing	5
Table 10-1	Maternal Specimen Collection and Storage by Visit.....	6
Table 10-2	Infant Specimen Collection and Storage by Visit	7
10.6.2	Remote Specimen Testing.....	8
10.6.3	LDMS Specimen Processing and Storage.....	8
10.7	Specimen Collection	9
10.7.1	Blood.....	9
10.7.2	Dried Blood Spot (DBS) Preparation and Storage	9
Table 10-3	HPTN 046 Required Laboratory Blood Assays Per Participant Visit.....	10
10.7.3	Breast Milk Collection	11
10.8	Infant HIV Testing	12
Figure 10-2	HIV Testing Algorithm for Infants 15 Months of Age or Younger	13
Figure 10-3	HIV Antibody Testing Algorithm for Infants Older than 15 Months of Age.....	14
10.9	Required Stored Specimens.....	15
10.10	Breast Milk Processing and Storage.....	15
10.11	Resistance Testing.....	16
10.12	Shipping Samples to the HPTN NL	16
10.12.1	IATA Shipping Regulations.....	17
10.12.2	Local Laboratory Monitoring.....	17
10.13	Quality Control and Quality Assurance Procedures.....	17
SECTION 11. ADVERSE EVENT REPORTING AND SAFETY MONITORING		11-1
11.1	Adverse Event Definitions	1
11.2	Adverse Events that Meet the Criteria for Expedited Reporting to DAIDS (EAEs).....	2
11.3	Adverse Event Severity Grading	3

11.3.1	Assigning Severity Grades of Case Report Forms	4
11.4	Adverse Event Relationship Assessment	5
11.5	Specific Adverse Event Documentation and Reporting Requirements for HPTN 046	5
Table 11-1	HPTN 046 Adverse Event Reporting and Additional Documentation Requirements.....	7
11.6	Abnormalities at Baseline (Pre-Existing conditions)	8
11.7	Lab Abnormalities.....	8
11.8	Follow-up Information on Adverse Events	8
11.9	Outcome of Adverse Events.....	9
11.10	Reporting Recurrent Adverse Events	9
11.11	Reporting Change in Severity of Adverse Events	9
11.12	Study Physician Assessment and Signature	9
11.13	Review of AE Reports.....	10
11.14	Contact Information for DAIDS Safety Office	10
11.15	HPTN 046 Safety Review and Oversight.....	10
11.16	Toxicity Management Procedures.....	11
11.17	Safety Distributions from DAIDS	11
SECTION 12. DATA COLLECTION		12-1
12.1	DataFax Overview.....	1
12.2	DataFax Form Completion.....	1
12.2.1	Guidelines	1
12.2.2	How to Mark Response Boxes	2
12.2.3	How to Record Numbers.....	2
12.2.4	How to Record Dates	3
12.2.5	How to Record Time	5
12.2.6	Data Corrections and Additions	5
12.2.7	How to Handle Missing and Unknown Data.....	6
12.2.8	Staff Initials/Date	7
12.3	Site Review of DataFax Forms	7
12.4	Transmitting DataFax Forms.....	7
12.5	HPTN 046-Specific Data Collection	8
12.5.1	Participant IDs.....	8
12.5.2	Visit Codes	8
12.5.3	Page Numbers	9
12.5.4	Study Visit Timing.....	9
12.5.5	Missed Visits.....	10
12.5.6	Termination and Reactivation	10
12.5.7	Interim Visit Codes	11
12.5.8	Form-Specific Instructions	19
SECTION 13. REPORTING PLAN FOR HPTN 046		13-1
13.1	Purpose of Reporting Plan.....	1
13.2	Procedures	1
13.3	Reports	1
Table 13-1	Reporting Schedule	2
13.3.1	Enrollment and Retention Report.....	3
13.3.2	Data Quality Control (QC) Report	4
13.3.3	Clinical Quality Control (QC) Report	5
13.3.4	Site Data Management Quality Report	6
13.3.5	Protocol Safety Review Team (PSRT) Report.....	7
13.3.6	Study Monitoring Committee (SMC) Report.....	8
13.3.7	Data Safety Monitoring Board (DSMB) Report	9

APPENDICES

- A. DAIDS SOP for Essential Documents
- B. DAIDS SOP for Source Documents
- C. Sample Study Staff Roster and Signature Sheet
- D. Sample Screening and Enrollment Log
- E. DAIDS Adult and Pediatric Toxicity Table
- F. 046 Supplemental Toxicity Table for Grading Fever, Malnutrition, and Rash
- G. Protocol Safety Review Team Procedures and Query Form
- H. Toxicity Management Table
- I. EAE Reporting Manual, EAE Form, and Form Instructions
- J. AE Reporting and Documentation Requirements Table
- K. Procedures for Participants Enrolled under Protocol Version 2.0